Phathom Pharmaceuticals, Inc. Common Stock
PHATPhathom Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for gastrointestinal diseases. The company aims to address unmet medical needs through innovative therapies, with a particular emphasis on conditions such as acid-related disorders.
Company News
U.S. stock futures declined on Thursday with investors awaiting Supreme Court ruling on tariffs and December jobs reports. AZZ surged on strong earnings, Northrop Grumman jumped on defense spending proposals, while Immuneering tumbled on disappointing trial data and Phathom dropped following stock offering announcement. Constellation Brands rose ...
Phathom Pharmaceuticals priced a $130 million underwritten public offering consisting of 6.875 million shares of common stock at $16.00 per share and 1.25 million pre-funded warrants at $15.999 per warrant. The offering is expected to close on January 9, 2026, with net proceeds intended for general corporate purposes including working capital, co...
Phathom Pharmaceuticals will participate in the American College of Gastroenterology's 2025 Annual Scientific Meeting, showcasing VOQUEZNA® (vonoprazan) as an approved treatment for Gastroesophageal Reflux Disease (GERD) through product theater presentations and exhibit booth interactions.
Phathom Pharmaceuticals will host a live webcast on October 30, 2025, at 8:00 am EDT to report its third quarter 2025 financial results and provide a business update, focusing on their gastrointestinal disease treatments.
Phathom Pharmaceuticals announced administrative changes to a Schedule 13D filing by Frazier Life Sciences, emphasizing that these changes do not represent a reduction in ownership position, but rather reflect reporting approach modifications.
